Ginoa inoa:venetoclax (ven ET oh klax)
Kapa inoa: ʻO Venclexta, Venclexta Hoʻomaka Pack

Hoʻohana ʻia ʻo Venetoclax e mālama i ka maʻi maʻi lymphocytic maʻi a i ʻole ka liʻiliʻi lymphocytic leukemia i nā pākeke. Hoʻohana wale ʻia ʻo Venetoclax a i hui pū ʻia me nā lāʻau lapaʻau ʻē aʻe e mālama i kēia mau maʻi.

Hoʻohana ʻia ʻo Venetoclax me ka azacitidine, decitabine, a i ʻole cytarabine e mālama i ka maʻi leukemia myeloid acute. Hoʻohana ʻia kēia hui ʻana i nā pākeke nona nā makahiki he 75 a ʻoi paha, a i ʻole hiki ke hoʻohana i ka chemotherapy maʻamau ma muli o nā kūlana olakino ʻē aʻe.

Hāʻawi ʻia ʻo Venetoclax i kekahi manawa ma hope o ka pau ʻole o nā lāʻau lapaʻau ʻē aʻe.

Hiki ke hoʻohana ʻia ʻo Venetoclax no nā kumu ʻaʻole i helu ʻia ma kēia alakaʻi lāʻau lapaʻau.

wehewehe

ʻO Venetoclax (ABT-199; GDC-0199) he mea hoʻopaneʻe Bcl-2 ikaika loa, koho a me ka waha me kahi Ki o lalo o 0.01 nM. Hoʻokumu ʻo Venetoclax i ka autophagy.

In Vitro

Venetoclax (ABT-199) potently pepehi FL5.12-BCL-2 cell (EC50=4 nM), Venetoclax (ABT-199) hōʻike nui nawaliwali hana ku e FL5.12-BCL-XL cell (EC50=261 nM). Hōʻike pū ʻo ABT-199 i ka koho ʻana i nā ʻano ʻelua-hybrid assays mammalian cellular, kahi e hoʻopau ai i nā paʻakikī BCL-2-BIM (EC50=3 nM) akā ʻoi aku ka liʻiliʻi i ka BCL-XL-BCL-XS (EC50=2.2).μM) a i ʻole MCL-1-NOXA paʻakikī.

Ma hope o ka nui o ka waha o 12.5 mg no kg ke kaumaha o ke kino i nā xenografts i loaʻa mai RS4; 11 cell (ALL), ʻo Venetoclax (ABT-199) ke kumu o ka hōʻemi ʻana i ka ulu ulu ʻana (TGImax) o 47% (P<0.001) a me ka ulu ʻana o ka tumor. lohi (TGD) o 26% (P<0.05)[1].

ʻO ka mālama ʻana i ka xenografted i hoʻokumu ʻia (he kumu hoʻohālike ʻiole xenograft o ka T-ALL cell line LOUCY) nā ʻōpū me Venetoclax (ABT-199) 100 mg/kg no nā lā 4 e hopena i ka hōʻemi nui ʻana o ke kaumaha leukemic.